Protein to control breast cancer progression identified
The University of Queensland News Jul 19, 2017
Switching off a protein produced in breast cancer cells can stop cancer progression, researchers from The University of Queensland have found.
Dr Iman Azimi from UQ School of Pharmacy and Mater Research Institute said, when breast cancer cells were made to stop producing a protein called TRPC1, some of the pathways important in breast cancer progression were deactivated.
ÂWe identified TRPC1 as a regulator of several pathways that, when activated by hypoxia, are critical in breast cancer progression, Dr Azimi said.
ÂAs breast cancers grow, their supply of oxygen can decline. This is called hypoxia.
ÂThis can trigger the breast cancer to become more aggressive and resistant to currently available therapies.Â
The new study has helped define a potential new therapeutic target for the control of breast cancer progression.
ÂThe work is most relevant to women who will develop breast cancer in the future, as these studies may enable the development of more effective therapies for breast cancers that become resistant to current therapies, Dr Azimi said.
ÂThis research is of global significance as it provides researchers a new understanding of the role of TRPC1 in the response of breast cancer cells to hypoxia and how breast cancers cells may become metastatic.Â
The researchers hope these results will have an impact on breast cancer research and the thousands of women who die every year from breast cancer.
ÂWe are very excited about these findings that we aim to be used in future drug development research to improve current therapeutic interventions, Dr Azimi said.
Dr Azimi completed the study with senior investigator Professor Greg Monteith from UQÂs School of Pharmacy.
The research was published in the Journal of Cell Science.
Go to Original
Dr Iman Azimi from UQ School of Pharmacy and Mater Research Institute said, when breast cancer cells were made to stop producing a protein called TRPC1, some of the pathways important in breast cancer progression were deactivated.
ÂWe identified TRPC1 as a regulator of several pathways that, when activated by hypoxia, are critical in breast cancer progression, Dr Azimi said.
ÂAs breast cancers grow, their supply of oxygen can decline. This is called hypoxia.
ÂThis can trigger the breast cancer to become more aggressive and resistant to currently available therapies.Â
The new study has helped define a potential new therapeutic target for the control of breast cancer progression.
ÂThe work is most relevant to women who will develop breast cancer in the future, as these studies may enable the development of more effective therapies for breast cancers that become resistant to current therapies, Dr Azimi said.
ÂThis research is of global significance as it provides researchers a new understanding of the role of TRPC1 in the response of breast cancer cells to hypoxia and how breast cancers cells may become metastatic.Â
The researchers hope these results will have an impact on breast cancer research and the thousands of women who die every year from breast cancer.
ÂWe are very excited about these findings that we aim to be used in future drug development research to improve current therapeutic interventions, Dr Azimi said.
Dr Azimi completed the study with senior investigator Professor Greg Monteith from UQÂs School of Pharmacy.
The research was published in the Journal of Cell Science.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
